Regeneron Pharmaceuticals (REGN) earnings
In the quarter ended June 2026, Regeneron Pharmaceuticals had revenue of $4.3B, up 16.7% on a year earlier, and diluted EPS of 12.23.
On July 30, 2026 it reported EPS of 12.53 against an estimate of 8.00 (beat).
The next report is expected on Friday, October 30, 2026 before the market opens, with EPS expected around 13.51.
Report dates
| Report | Date | Time | EPS estimate | EPS reported |
|---|---|---|---|---|
| Next | Fri Oct 30, 2026 | Before open | 13.51 | — |
| Last | Thu Jul 30, 2026 | Before open | 8.00 | 12.53 |
Dates from company announcements and exchange calendars; estimates are the consensus where available. See the full earnings calendar.
Quarterly results
The last 12 quarters from Regeneron Pharmaceuticals's 10-Q and 10-K filings with the SEC. Growth is against the same quarter a year earlier. EPS here is GAAP diluted EPS as filed; the reported EPS compared with estimates above can be on the company's adjusted basis, so the two can differ.
| Quarter ended | Revenue | Growth | EPS (diluted) | Growth | Op. margin | Filed |
|---|---|---|---|---|---|---|
| Jun 30, 2026 | $4.3B | +16.7% | 12.23 | -4.5% | 30.1% | 2026-07-30 |
| Mar 31, 2026 | $3.6B | +19.0% | 6.75 | -7.2% | 17.8% | 2026-04-29 |
| Dec 31, 2025 | $3.9B | +2.5% | — | — | 22.7% | 2026-02-04 |
| Sep 30, 2025 | $3.8B | +0.9% | 13.62 | +18.0% | 27.3% | 2025-10-28 |
| Jun 30, 2025 | $3.7B | +3.6% | 12.81 | +3.2% | 29.4% | 2025-08-01 |
| Mar 31, 2025 | $3.0B | -3.7% | 7.27 | +15.9% | 19.5% | 2025-04-29 |
| Dec 31, 2024 | $3.8B | +10.3% | — | — | 26.1% | 2025-02-05 |
| Sep 30, 2024 | $3.7B | +10.6% | 11.54 | +29.8% | 31.7% | 2024-10-31 |
| Jun 30, 2024 | $3.5B | +12.3% | 12.41 | +46.0% | 30.2% | 2024-08-01 |
| Mar 31, 2024 | $3.1B | -0.5% | 6.27 | -12.6% | 23.9% | 2024-05-02 |
| Dec 31, 2023 | $3.4B | +0.6% | — | — | 28.3% | 2024-02-05 |
| Sep 30, 2023 | $3.4B | +14.5% | 8.89 | -23.8% | 33.0% | 2023-11-02 |
Questions
When does Regeneron Pharmaceuticals report earnings?
Regeneron Pharmaceuticals's next earnings report is expected on October 30, 2026 before the market opens.
How did Regeneron Pharmaceuticals do last quarter?
In the quarter ended June 2026, Regeneron Pharmaceuticals had revenue of $4.3B, up 16.7% on a year earlier, and diluted EPS of 12.23.
From Regeneron Pharmaceuticals's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.